Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Monogram Orthopaedics Inc. Common Stock (MGRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: MGRM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.7
1 Year Target Price $5.7
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.27% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.77M USD | Price to earnings Ratio - | 1Y Target Price 5.7 |
Price to earnings Ratio - | 1Y Target Price 5.7 | ||
Volume (30-day avg) 1 | Beta 0.41 | 52 Weeks Range 1.92 - 4.21 | Updated Date 07/9/2025 |
52 Weeks Range 1.92 - 4.21 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -67.36% | Return on Equity (TTM) -146.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 104835169 | Price to Sales(TTM) 243.53 |
Enterprise Value 104835169 | Price to Sales(TTM) 243.53 | ||
Enterprise Value to Revenue 230.43 | Enterprise Value to EBITDA -5.1 | Shares Outstanding 35687900 | Shares Floating 26085736 |
Shares Outstanding 35687900 | Shares Floating 26085736 | ||
Percent Insiders 33.52 | Percent Institutions 5.15 |
Upturn AI SWOT
Monogram Orthopaedics Inc. Common Stock
Company Overview
History and Background
Monogram Orthopaedics Inc. was founded in 2015. It is focused on developing robotic surgical technology and personalized implants for joint reconstruction.
Core Business Areas
- Robotic Surgical Systems: Development and commercialization of a robotic surgical platform for total joint arthroplasty.
- Personalized Implants: Designing and manufacturing patient-specific implants tailored to individual anatomy.
Leadership and Structure
Benjamin Sexson is the CEO. The company operates with a structure common for a small-cap medical device firm, emphasizing R&D and commercialization.
Top Products and Market Share
Key Offerings
- mBu00f4s System: A robotic surgical system intended for knee replacement procedures. Currently, the system is not yet commercially available and therefore has 0% market share. Competitors include Stryker (SYK), Zimmer Biomet (ZBH), and Smith & Nephew (SNN).
- Personalized Knee Implants: Implants designed using patient-specific data to improve fit and surgical outcomes. Not yet commercially available and market share is 0%. Competitors are companies which are mentioned above.
Market Dynamics
Industry Overview
The orthopedic implant and robotic surgery market is growing, driven by an aging population, advancements in technology, and demand for minimally invasive procedures.
Positioning
Monogram Orthopaedics is positioned as an innovator in personalized joint reconstruction, leveraging robotic technology and custom implants to improve surgical outcomes. Their competitive advantage lies in their patient-specific approach.
Total Addressable Market (TAM)
The global joint reconstruction market is estimated to be tens of billions of dollars. Monogram Orthopaedics aims to capture a portion of this market with its robotic system and personalized implants, focusing initially on knee arthroplasty.
Upturn SWOT Analysis
Strengths
- Innovative robotic surgical platform
- Personalized implant design capabilities
- Potential for improved surgical outcomes
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization experience
- High R&D expenses
- Dependence on regulatory approvals
- Currently pre-revenue
Opportunities
- Expanding applications of robotic surgery in orthopedics
- Partnerships with hospitals and orthopedic surgeons
- Increasing adoption of personalized implants
- Potential for acquisitions by larger medical device companies
Threats
- Competition from established orthopedic device companies
- Regulatory hurdles
- Technological advancements by competitors
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- SYK
- ZBH
- SNN
Competitive Landscape
Monogram Orthopaedics faces intense competition from established players. Its competitive advantage lies in its personalized approach, but it needs to overcome barriers to entry like regulatory approvals and market acceptance.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is non-existent as the company is in a pre-revenue stage focusing on R&D.
Future Projections: Future growth relies on regulatory approval and successful commercialization. Analyst projections vary significantly due to the inherent risks associated with the company's stage of development. Projections are unavailable.
Recent Initiatives: Focus on securing regulatory approvals for the mBu00f4s System, expanding clinical research, and establishing manufacturing capabilities.
Summary
Monogram Orthopaedics is a development-stage company with an innovative robotic surgical platform and personalized implant technology. It faces high execution risk, including regulatory approvals and market adoption. Its financial health depends on managing cash burn and securing future funding. While its technology holds promise, investors should be aware of the significant uncertainties and competition in the orthopedic market. Successful commercialization is crucial for long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monogram Orthopaedics Inc. Common Stock
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2023-05-18 | Chairman of the Board, President & CEO Mr. Benjamin Sexson C.F.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 27 | |
Full time employees 27 | |||
Monogram Technologies Inc. engages in developing surgical robot to enable placement of patient optimized orthopedic implants in the United States. It intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.